Search

Shigella is the leading bacterial cause of diarrhea worldwide, with increasing levels of antibiotic resistance. The greatest burden is among children aged <5 years in low- and middle-income countries, and efforts are ongoing to develop vaccines against this pathogen. One of the challenges associated with the development of a vaccine against Shigella is the need for a multivalent vaccine covering the most prevalent Shigella serotypes. Epidemiologic studies to better understand the prevalence of the Shigella serotypes and inform vaccination schedules are very useful, with clinical data showing the ability of vaccines to elicit cross-reactive antibodies. Here, we set up a Luminex-based method able to reproducibly measure antibodies specific to 13 Shigella antigens in human sera. This method will allow the rapid collection of large amounts of data based on the analysis of serum samples from vaccinated individuals or people naturally exposed to Shigella , supporting the development of a vaccine against this disease. [ABSTRACT FROM AUTHOR]